- 01/28/2020
- 01/10/2020
- LAUNCH OF ANTICANCER AGENT HALAVEN® IN CHINA
- 01/06/2020
- FYCOMPA® FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES LAUNCHED IN CHINA
- 12/23/2019
- U.S. FDA APPROVES EISAI’S DAYVIGO™ (LEMBOREXANT) FOR TREATMENT OF INSOMNIA IN ADULT PATIENTS
- 12/02/2019
- ADDITIONAL INDICATION FOR LENVIMA® (LENVATINIB) FOR DIFFERENTIATED THYROID CANCER ACCEPTED IN CHINA
- 12/02/2019
- Eisai China Inc. is certified as the “Top Employers China 2020”
- 12/01/2019
- Launch Meeting of the Third-Generation Antiepileptic Drug of Fycompa (Perampanel) in China
- 11/26/2019
- Eisai China Pharmaceutical Co., Ltd. Carried out Scholarships and Grants Program in Peking University Health Science Center for 8 Consecutive Years
- 11/26/2019
- EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT 73RD AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
- 11/05/2019
- EISAI TRANSFERS RIGHTS TO RECEIVE ROYALTIES OUTSIDE OF JAPAN FOR EZH2 INHIBITOR TAZEMETOSTAT TO ROYALTY PHARMA
